Concord Biotech Limited CONCORDBIO.NS · Stock Open Concord Biotech Limited in new tab
Concord Biotech Limited Analysis (CONCORDBIO.NS)
Is Concord Biotech Limited a good investment? Concord Biotech Limited (CONCORDBIO.NS) is currently trading at 1355.90 INR. Market analysts have a consensus price target of 1550.60 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 48.27. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Concord Biotech Limited is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is 42.54.
For income investors, Concord Biotech Limited pays a dividend yield of 0.55%. With a payout ratio of 37%, the dividend appears sustainable.
Investor FAQ
Does Concord Biotech Limited pay a dividend?
Yes, it pays an annual dividend of 7.55 INR (0.55% yield).
What asset class is Concord Biotech Limited?
Concord Biotech Limited is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of 28.98.
Company Profile
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
| Year | Total Dividends |
|---|---|
| ▸2027 |
7.55 INR
|
| Aug. 30, 2027 (estimated) | 7.5500 |
| ▸2026 |
18.25 INR
|
| Oct. 9, 2026 (estimated) | 10.7000 |
| Aug. 30, 2026 | 7.5500 |
| ▸2025 |
10.70 INR
|
| Oct. 9, 2025 | 10.7000 |
| ▸2024 |
8.75 INR
|
| July 29, 2024 | 8.7500 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Concord Biotech Limited | Aug 30, 2026 | Paid | 7.55 INR |
Community Discussion